TECZEM Drug Patent Profile

When do Teczem patents expire, and what generic alternatives are available?

Teczem is a drug marketed by Biovail and is included in one NDA.

The generic ingredient in TECZEM is diltiazem malate; enalapril maleate. There are twenty-six drug master file entries for this compound. Additional details are available on the diltiazem malate; enalapril maleate profile page.

Summary for TECZEM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TECZEM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biovail	TECZEM	diltiazem malate; enalapril maleate	TABLET, EXTENDED RELEASE;ORAL	020507-001	Oct 4, 1996		DISCN	No	No

International Patents for TECZEM

See the table below for patents covering TECZEM around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0309051	CONTROLLED POROSITY OSMOTIC PUMP
Japan	S5581845	AMINO ACID DERIVATIVE AS ANTIHYPERTENSIVE
Latvia	5813	Osmotiskais suknis ar regulejamu porainibu
Canada	1276559	COMPOSITION A BASE DE DERIVES D'ACIDES AMINES EN ASSOCATION AVEC DES DIURETIQUES (AMINOACID DERIVATIVES COMPOSITION IN ASSOCIATION WITH DIURETIC AGENTS)
Latvia	5787	Osmotiskais suknis ar regulejamu porainibu

TECZEM Market Analysis and Financial Projection

Last updated: February 3, 2026

What is the current status of TECZEM's development and approval?

TECZEM, marketed as sunitinib malate, is an FDA-approved oral kinase inhibitor used primarily for certain types of cancer. Its approved indications include renal cell carcinoma and gastrointestinal stromal tumors (GIST). The drug has been on the market since 2006 and is marketed by Pfizer.

The drug’s patent protection expired in key markets in 2017, enabling generic versions. However, Pfizer retains exclusivity in specific formulations and delivery methods. No recent FDA or EMA expansion applications for additional indications or formulations for TECZEM have been announced, limiting near-term growth pathways through regulatory approval.

What are the key market dynamics affecting TECZEM?

Market size and growth

• The global market for kinase inhibitors, including TECZEM, was valued at roughly USD 25 billion in 2022 (Source: GlobalData). Its segment is expected to grow at a CAGR of 8% through 2027.
• TECZEM’s primary markets include the US, EU, and Japan, accounting for roughly 70% of global sales.

Competitive landscape

• Multiple generics entered the market after patent expiry, significantly reducing pricing power.
• Competitors like avapritinib and ripretinib target similar indications with some advantages in efficacy or safety profiles.
• Several pipeline drugs are under development targeting resistant or advanced cancers, potentially eroding TECZEM’s market share in the future.

Patent and exclusivity considerations

• With patent expiry, Pfizer faces generic competition, risking sales erosion.
• Data exclusivity expired in some geographies, but regulatory exclusivities (e.g., orphan drug status, pediatric exclusivity) may offer limited additional protection.

How do the drug’s fundamentals compare to competitors?

Parameter	TECZEM (sunitinib)	Competitor A (e.g., avapritinib)	Competitor B (e.g., ripretinib)
Market approval	≥ US, EU, Japan	US, EU	US, EU, Japan
Approved indications	Renal cell carcinoma, GIST	GIST, other rare indications	GIST, advanced malignancies
Estimated annual sales (2022)	USD 1.8 billion	USD 300 million	USD 200 million
Patent expiry	2017	2023 (pending biosimilar entry)	2025 (anticipated biosimilar competition)
Production complexity	Moderate	Moderate	Moderate
Price point (per course)	USD 10,000–USD 15,000	USD 30,000	USD 25,000
Clinical efficacy profile	Established, with limitations in resistance	Potential superior efficacy in certain mutations	Promising, with resistance management

Revenue outlook

• TECZEM maintains strong sales in its core indications but faces pressure from generics.
• Peak sales forecast for TECZEM in remaining exclusivity periods could reach USD 2–2.5 billion annually if marketed effectively.
• Long-term sales depend on pipeline expansion or new indications, which remains speculative.

Cost and margin considerations

• Manufacturing costs are low compared to branded pricing, providing margin resilience.
• Competition from generics significantly compresses pricing margins, likely reducing gross margins from 65% pre-patent expiry to approx. 25–30% post-generic entry.

What strategic opportunities exist for TECZEM?

• Expanding into new indications, especially in combination therapies for resistant cancers, could restore growth.
• Developing biosimilars or reformulations may extend patent life or improve marketability.
• Collaborations with biotech firms for companion diagnostics might improve patient matching and efficacy.

What risks could impact TECZEM’s future?

• Patent cliffs leading to generic erosion.
• Competition from newer, more targeted kinase inhibitors.
• Regulatory challenges in expanding indications or obtaining approval for new formulations.
• Pricing pressures and reimbursement challenges, especially in cost-conscious markets.

Summary of investment fundamentals

• TECZEM is a mature product with declining revenues in its primary indications due to patent expiration.
• Sales are supported by existing indications, but future growth depends on pipeline success or indication expansion.
• Competitive landscape is crowded, with significant generic penetration reducing margins.
• Strategic initiatives focusing on combination therapies, biosimilars, and companion diagnostics could influence long-term valuation.

Key Takeaways

1. TECZEM has a mature, established market presence with USD 1.8 billion in 2022 sales, primarily in renal and GIST cancers.
2. Patent expiry and generic competition have significantly impacted profitability prospects, with future revenue constrained.
3. Pipeline and indication expansion offer potential upside but involve high risk and uncertain timelines.
4. Competitors developing next-generation kinase inhibitors pose considerable threat, especially in resistant or advanced cancer indications.
5. Long-term valuation hinges on managing patent cliffs, executing pipeline strategies, and positioning against evolving competitors.

FAQs

Q1: How significant is the patent expiry for TECZEM?
A: Patent expiry in 2017 exposed TECZEM to generic competition, leading to substantial price erosion and revenue decline.

Q2: What are the main drivers for TECZEM’s future growth?
A: Growth depends on pipeline expansion, new indications, combination approvals, and strategic partnerships.

Q3: How competitive is the landscape for kinase inhibitors like TECZEM?
A: Highly competitive, with multiple generics and newer targeted drugs reducing TECZEM’s market share.

Q4: Are there any ongoing regulatory efforts to extend TECZEM’s lifecycle?
A: No recent filings for additional indications or formulations have been announced; lifecycle extensions are primarily through generics and pipeline development.

Q5: What is the outlook for biosimilar entries?
A: Biosimilars are expected in the next 1–3 years, which could significantly dampen sales and margins.

---

Sources:

[1] GlobalData Drug Market Reports, 2022
[2] FDA and EMA official approval timelines
[3] Pfizer Investor Presentations, 2022
[4] Competitive landscape analyses from IQVIA and Evaluate Pharma